Daniel J. Brennan Sells 67,333 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX - Get Free Report) CFO Daniel J. Brennan sold 67,333 shares of the firm's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the sale, the chief financial officer now owns 225,808 shares in the company, valued at approximately $23,764,033.92. This represents a 22.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Boston Scientific Trading Down 0.9 %

BSX stock traded down $0.93 during trading on Friday, reaching $104.44. 5,512,880 shares of the stock were exchanged, compared to its average volume of 6,033,932. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The business has a 50 day moving average price of $97.98 and a 200-day moving average price of $89.27. Boston Scientific Co. has a 1 year low of $65.52 and a 1 year high of $107.17. The firm has a market capitalization of $154.12 billion, a price-to-earnings ratio of 83.55, a P/E/G ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on BSX. Mizuho raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Thursday, October 24th. Raymond James raised their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research report on Thursday, February 6th. Royal Bank of Canada raised their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company increased their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, Barclays increased their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $107.39.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently made changes to their positions in BSX. Creative Planning increased its position in shares of Boston Scientific by 7.7% during the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider's stock valued at $17,113,000 after acquiring an additional 14,663 shares during the last quarter. Global Retirement Partners LLC increased its position in shares of Boston Scientific by 11.5% during the third quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider's stock valued at $366,000 after acquiring an additional 449 shares during the last quarter. Stratos Wealth Advisors LLC increased its position in shares of Boston Scientific by 8.9% during the third quarter. Stratos Wealth Advisors LLC now owns 6,419 shares of the medical equipment provider's stock valued at $538,000 after acquiring an additional 522 shares during the last quarter. Capital Investment Advisors LLC acquired a new stake in shares of Boston Scientific during the third quarter valued at about $217,000. Finally, Northwest Investment Counselors LLC acquired a new stake in shares of Boston Scientific during the third quarter valued at about $38,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.